Average Organ Dose Research Articles

Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy.

177Lu can be imaged after administration using SPECT/CT. Most work to date has focused on using posttreatment imaging to measure normal organ and tumor dose. We aimed to assess the impact of posttreatment SPECT/CT on the management of patients undergoing 177Lu-prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT). Methods: In this retrospective study, 122 patients underwent PSMA RPT with subsequent SPECT/CT 24 h after treatment. We determined a qualitative response at each cycle and reviewed patient charts to assess the impact that posttreatment SPECT/CT had on patient management. Changes in patient management were classified as changes on the basis of progression and response, and specific cycles when they occurred were noted. Miscellaneous changes in patient management were also evaluated. Results: Among the 122 consecutive patients examined, 42%-56% exhibited stable disease, whereas 19%-39% of patients exhibited response on visual assessment across treatment cycles. In total, 49% (n = 60) of patients experienced changes in management, of which 57% (n = 34) were due to progression, 40% (n = 24) were due to response, and 3% (n = 2) were due to miscellaneous changes. Changes due to disease progression were observed mostly after cycles 2 and 4. Changes due to response to RPT occurred mostly after cycles 3 and 4. Conclusion: At our center, 49% of patients experienced changes in management based on posttreatment SPECT/CT, and most of these changes occurred at cycles 2 and 4. Integrating posttreatment SPECT/CT into routine PSMA RPT protocols can aid in patient management.

The MIRD Schema for Radiopharmaceutical Dosimetry: A Review.

Internal dosimetry evaluates the amount and spatial and temporal distributions of radiation energy deposited in tissue from radionuclides within the body. Historically, nuclear medicine had been largely a diagnostic specialty, and the implicitly performed risk-benefit analyses have been straightforward, with relatively low administered activities yielding important diagnostic information whose benefit far outweighs any potential risk associated with the attendant normal-tissue radiation doses. Although dose estimates based on anatomic models and population-average kinetics in this setting may deviate rather significantly from the actual normal-organ doses for individual patients, the large benefit-to-risk ratios are very forgiving of any such inaccuracies. It is in this context that the MIRD schema was originally developed and has been largely applied. The MIRD schema, created and maintained by the MIRD committee of the Society of Nuclear Medicine and Molecular Imaging, comprises the notation, terminology, mathematic formulas, and reference data for calculating tissue radiation doses from radiopharmaceuticals administered to patients. However, with the ongoing development of new radiopharmaceuticals and the increasing therapeutic application of such agents, internal dosimetry in nuclear medicine and the MIRD schema continue to evolve-from population-average and organ-level to patient-specific and suborgan to voxel-level to cell-level dose estimation. This article will review the basic MIRD schema, relevant quantities and units, reference anatomic models, and its adaptation to small-scale and patient-specific dosimetry.

Multi-planner validation of RapidPlan knowledge-based model for volumetric modulated arc therapy in prostate cancer.

To investigate the performance of a model-based optimization process for volumetric modulated arc therapy (VMAT) applied to prostate cancer patients with the multi-planner. The 120 prostate plans for VMAT treatment were entered into the database system of the RapidPlan (RP) knowledge-based treatment planning. The treatment planning data for each plan was used to create and train the RP model. Twelve prostate cancer cases were selected and were used for planning by a manual of 12 planners based on the clinical protocol for dose constraints. Then, the treatment plans for each patient were compared with the RP model plans and analyzed with Wilcoxon tests. On average, the RP models can estimate comparable doses among all planner plans and clinical plans for the PTV, which Dmax , D95% , D98% , HI, and CI were used to evaluate. For the normal organ doses of the bladder, rectum, penile bulb, and femoral head, all RP model plans showed comparable or better dose sparing than all planner plans and clinical plans. Moreover, the average planning time of the RP model was faster than manual plans by about two times. The RP model can significantly reduce the variation dose of the normal organs compared with the manual plans among the planners. The automated plans of the RP model might benefit from further fine-tuning of the dose constraints of the normal organs, although both procedure plans are acceptable and fulfill the clinical protocol goals so that the RP model can enhance the efficacy and quality of plans.

Effect of tin spectral filtration on organ and effective dose in CT colonography and CT lung cancer screening.

Studies of tin spectral filtration have demonstrated potential in reducing radiation dose while maintaining image quality for unenhanced computed tomography (CT) scans. The extent of dose reduction, however, was commonly measured using the change in the scanner's reported CTDIvol . This method does not account for how tin filtration affects patient organ and effective dose. To investigate the effect of tin filtration on patient organ and effective dose for CT Lung Cancer Screening (LCS) and CT Colonography (CTC). A previously-developed Monte Carlo program was adapted to model a 96-row CT scanner (Somatom Force, Siemens Healthineers) with tin filtration capabilities at 100kV (100Sn) and 150kV (150Sn). The program was then validated using experimental CTDIvol measurements at all available kV (70-150kV) and tin-filtered kV options (100Sn and 150Sn). After validation, the program simulated LCS scans of the chest and CTC scan of the abdomen-pelvis for a population of 53 computational patient models from the extended cardiac-torso family. Each scan was performed using three different spectra: 120kV, 100Sn, and 150Sn. CTDIvol -normalized organ doses and DLP-normalized effective doses, commonly referred to as dose conversion factors, were compared between the different spectra. For all LCS and CTC scans, CTDIvol -normalized organ doses and DLP-normalized effective doses increased with increasing beam hardness (120kV, 100Sn, 150 Sn). For LCS, relative for 120kV, conversion factors for 100Sn produced a median increase in effective dose of 9%, with organ dose increases of 8% to lung, 5% to breast, 15% to thyroid, and 3% to skin. Conversion factors for 150Sn produced a median increase in effective dose of 20%, with organ dose increases of 16%, 18%, 26%, and 12% to these same organs, respectively. For CTC, relative for 120kV, conversion factors for 100Sn produced a median increase in effective dose of 12%, with organ dose increases of 9% to colon, 10% to liver, 11% to stomach, and 4% to skin. Conversion factors for 150Sn produced a median increase in effective dose of 21%, with organ dose increases of 16%, 17%, 19%, and 10% to these same organs, respectively. Results show that dose conversion factors are greater when using tin filtration and should be considered when evaluating tin's potential for dose reduction.

Dose Constraints and Planning Considerations for Thoracic Radiation Therapy: Delphi Consensus from a National Survey of Experts

Many physicians refer to trial protocols or published guidelines (NCCN, QUANTEC, HyTEC) for dose-volume histogram (DVH) metrics. However, there may be variation in implementing these metrics during plan optimization. Some studies have suggested better outcomes for patients treated at high-volume, high-expertise centers. These differences may in part be due to greater standardization or center-specific treatment planning processes. We surveyed radiation oncologists with stated thoracic-specific expertise using the Delphi method to formulate consensus DVH metrics that would be considered ideal for high-quality radiation treatment plans. Thoracic radiation oncology experts were identified using departmental websites of ACGME-accredited radiation oncology programs. After confirming their expertise, panelists were invited to submit their institutional templates and complete three rounds of questions related to normal organ dose constraints, target coverage metrics, prescribing practices, and other planning considerations. Queried radiation schemes included conventional fractionation, twice-daily fractionation, and stereotactic body radiation therapy (3 and 5 fractions). Preliminary consensus statements were generated using median values for DVH metrics and were iteratively refined in subsequent surveys. Consensus was pre-defined as ≥75% agreement among panelists. A total of 194 experts were invited, and 100 agreed to participate. The panel was 28% female and included experts from 29 states with a median of 11 years of clinical experience (IQR 6-19). 89% specialized in 1-2 disease sites. Response rates for the Demographics, round 1, 2, and 3 surveys were 83%, 78%, 57%, and 55%, respectively. 93% of panelists believed that DVH metrics should provide thresholds for both optimal and acceptable criteria for treatment planning. 49 of the 96 proposed normal tissue dose constraint statements were iterated to consensus (Table 1), and 5 of 7 proposed target coverage metric statements achieved consensus. This study highlights the heterogeneity in metrics used by thoracic radiation oncologists and provides levels of consensus on ideal and acceptable dose constraints as guidance for treatment planning. Future directions include using these statements to develop prescription templates and acceptance criteria for treatment planning systems for widespread use as well as extending this Delphi approach to additional disease sites.

Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project

PurposeDosimetry is rarely performed for the treatment of differentiated thyroid cancer patients with Na[131I]I (radioiodine), and information regarding absorbed doses delivered is limited. Collection of dosimetry data in a multi-centre setting requires standardised quantitative imaging and dosimetry. A multi-national, multi-centre clinical study was performed to assess absorbed doses delivered to normal organs for differentiated thyroid cancer patients treated with Na[131I]I.MethodsPatients were enrolled in four centres and administered fixed activities of 1.1 or 3.7 GBq of Na[131I]I using rhTSH stimulation or under thyroid hormone withdrawal according to local protocols. Patients were imaged using SPECT(/CT) at variable imaging time-points following standardised acquisition and reconstruction protocols. Whole-body retention data were collected. Dosimetry for normal organs was performed at two dosimetry centres and results collated.ResultsOne hundred and five patients were recruited. Median absorbed doses per unit administered activity of 0.44, 0.14, 0.05 and 0.16 mGy/MBq were determined for the salivary glands of patients treated at centre 1, 2, 3 and 4, respectively. Median whole-body absorbed doses for 1.1 and 3.7 GBq were 0.05 Gy and 0.16 Gy, respectively. Median whole-body absorbed doses per unit administered activity of 0.04, 0.05, 0.04 and 0.04 mGy/MBq were calculated for centre 1, 2, 3 and 4, respectively.ConclusionsA wide range of normal organ doses were observed for differentiated thyroid cancer patients treated with Na[131I]I, highlighting the necessity for individualised dosimetry. The results show that data may be collated from multiple centres if minimum standards for the acquisition and dosimetry protocols can be achieved.

Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression

BackgroundThe accumulation of 177Lu-DOTATATE might be influenced by the amount of administered peptide in relation to the tumor somatostatin receptor expression. The effect of the administered peptide mass on the resulting absorbed dose in tumors and normal organs has not previously been assessed in relation to the patients’ tumor load.MethodPatients with small intestinal (n = 141) and pancreatic (n = 62) neuroendocrine tumors (NETs) who underwent PRRT were selected for retrospective evaluation. All patients had received 7.4 GBq 177Lu-DOTATATE, and the amount of administered peptide in the preparation varied from 93 to 456 µg. The absorbed dose in tumors and normal tissue at the first PRRT cycle was calculated, based on SPECT-measurements at day 1, 4, and 7 post-infusion. The total tumor somatostatin receptor expression (tTSSTRE) was calculated on SPECT after 24 h by multiplying the functional tumor volume, delineated by 42% cut-off VOIs of the highest activity, with the SUVmean for the respective tumor VOIs. Spearman’s rank correlation analyzed any relationship between the administered amount of peptide and the absorbed dose in tumors and normal organs, in relation to the patients’ tTSSTRE.ResultsThere was no correlation between the amount of peptide and any of the tested parameters in relation to tTSSTRE.ConclusionIn this retrospective analysis, no correlation between the amount of administered peptide in the 177Lu-DOTATATE preparation and the absorbed radiation doses in tumors and normal tissues was demonstrated in relation to the total tumor SSTR expression.

Feasibility of size-specific organ-dose estimates based on water equivalent diameter for common head CT examinations: a Monte Carlo study

Computed tomography dose index (CTDI) is an unreliable dose estimate outside of the standard CTDI phantom diameters (16 and 32 cm). Size-specific dose estimate (SSDE) for head computed tomography (CT) examination was studied in the American Association of Physicists in Medicine Report 293 to provide SSDE coefficient factors based on water equivalent diameter as size metrics. However, it is limited to one protocol and for a fully irradiated organ. This study aimed to evaluate the dependency of normalized organ dose (ND) on water equivalent diameter as a size metric in three common protocols: routine head, paranasal sinus, and temporal bone. CTDIw measurements were performed for outlined protocols in the Siemens Emotion 16-slice-configuration scanner. Geant4 Application for Tomographic Emission Monte Carlo simulation platform, coupled with ten GSF patient models, was used to estimate organ doses. CT scanner system was modeled. Helical CT scans were simulated using constructor scan parameters and calculated scan lengths of each patient model. Organ doses provided by simulations were normalized to CTDIvol. The water equivalent diameters (D w) of patient models were obtained via relationships between D w and both effective diameter for a sample of patients’ data.NDs received by fully, partially, and non-directly irradiated organs were then reported as a function of D w. For fully irradiated organs, brain (R 2 > 0.92), eyes (R 2 > 0.88), and eye lens (R 2 > 0.89) correlate well with D w. For the rest of the results, a poor correlation was observed. For partially irradiated organs, the exception was scalp (R 2 = 0.93) in temporal bone CT. For non-directly irradiated organs, the exception was thyroid (R 2 > 0.90) and lungs (R 2 > 0.91) in routine head CT. ND correlates well in routine head CT than other protocols. For the most part, no relationship seems to exist between R 2 and scan percentage coverage. The results have revealed additional factors that may influence the ND and D w relationship, which explains the need for more studies in the future to investigate the effect of scan conditions and organ anatomy variation.

Development of a generalized method to allow the estimation of doses to the ICRP reference adults from CT, on the basis of normalized organ and CTDI dose data determined by Monte Carlo calculation for a range of contemporary scanners

Objective. Development of a method to provide organ and effective dose coefficients to reference adults for any CT scanner based on values of CTDI measured both in air and in standard CT dosimetry phantoms. Approach. Results from previous Monte Carlo simulations for a range of contemporary CT scanners have been analyzed to provide linear models relating values of organ dose (normalized to CTDI free-in-air), for each slab of 3 reference phantoms (ICRP Male/Female, and AH hermaphrodite), to similarly normalized values of CTDI in standard CT dosimetry phantoms. Three methods have been investigated to apply the models to values of CTDI for a ‘new’ scanner not previously simulated: a Generic approach using averaged normalized organ dose profiles for whole body exposure of the phantoms; and two processes for matching the scanner, on the basis of normalized organ doses or effective dose ( n E 103,phan ), to one of the 102 sets of dose coefficients previously calculated for 12 contemporary CT scanner models, from 4 manufacturers, operating under a range of conditions. Main results. The merit of each method has been quantitatively assessed when applied to both the present contemporary scanners with each test data set being excluded in turn during the matching process, and also to 3 previously-simulated older scanners. Whereas all three methods appear viable, with all doses being within 1% and 10% for the contemporary and old scanners respectively, matching to n E 103,phan is overall the approach preferred in practice, yielding an uncertainty of around 6% in estimated values of n E 103,phan . The present methodology also provides superior performance when compared against some other common normalization factors for E 103,phan . Significance. The CT dose model and the data sets will be incorporated into a new CT dosimetry tool that will be made available from UKHSA in support of facilitating improvements in patient protection.

CT scanner-specific organ dose coefficients generated by Monte Carlo calculation for the ICRP adult male and female reference computational phantoms

Objective. Provide analyses of new organ dose coefficients (hereafter also referred to as normalized doses) for CT that have been developed to update the widely-utilized collection of data published 30 years ago in NRPB-SR250. Approach. In order to reflect changes in technology, and also ICRP recommendations concerning use of the computational phantoms adult male (AM) and adult female (AF), 102 series of new Monte Carlo simulations have been performed covering the range of operating conditions for 12 contemporary models of CT scanner from 4 manufacturers. Normalized doses (relative to free air on axis) have been determined for 39 organs, and for every 8 mm or 4.84 mm slab of AM and AF, respectively. Main results. Analyses of results confirm the significant influence (by up to a few tens of percent), on values of normalized organ (or contributions to effective dose (E 103,phan)), for whole body exposure arising from selection of tube voltage and beam shaping filter. Use of partial (when available) rather than a Full fan beam reduced both organ and effective dose by up to 7%. Normalized doses to AF were larger than corresponding figures for AM by up to 30% for organs and by 10% for E 103,phan. Additional simulations for whole body exposure have also demonstrated that: practical simplifications in the main modelling (point source, single slice thickness, neglect of patient couch and immobility of phantom arms) have sufficiently small (<5%) effect on E 103,phan; mis-centring of the phantom away from the axis of rotation by 5 mm (in any direction) leads to changes in normalized organ dose and E 103,phan by up to 20% and 6%, respectively; and angular tube current modulation can result in reductions by up to 35% and <15% in normalized organ dose and E 103,phan, respectively, for 100% cosine variation. Significance. These analyses help advance understanding of the influence of operational scanner settings on organ dose coefficients for contemporary CT, in support of improved patient protection. The results will allow the future development of a new dose estimation tool.

Target volume coverage in clinically designed radiotherapy plan of post-mastectomy adjuvant radiotherapy of breast cancer patients in comparison with radiation therapy oncology group-based contoured plan: A dosimetric study.

Conventional field radiotherapy based on anatomical landmarks has been the traditional treatment for breast cancer. Having proven efficacy, it is still the current standard of treatment. The Radiation Therapy Oncology Group (RTOG) has published guidelines for contouring target volumes in postmastectomy patients. The impact of this guideline in the current clinical practice is less known; hence, we have analyzed dose-volume histograms (DVHs) for these plans and compared them with the proposed treatment plans to treat RTOG-defined targets. RTOG consensus definitions were used to contour the target volumes in 20 previously treated postmastectomy patients. The prescription was 42.4 Gy in 16 fractions. DVHs were generated from clinically designed plans that had actually been delivered to each patient. For comparing dose to target volumes, new plans were generated with the goal of covering 95% of volume to 90% of prescribed dose. In RTOG contoured Group, coverage improved for the supraclavicular (V90 = 83 vs. 94.9%, P < 0.05) and chest wall (V90 = 89.8 vs. 95.2%, P < 0.05). Axillary nodal coverage improved for Level-1(V90 = 80.35 vs. 96.40%, P < 0.05), Level-II (V90 = 85.93 vs. 97.09%, P < 0.05) and Level III (V90 = 86.67 vs. 98.6%, P < 0.05). The dose to the ipsilateral lung is increased (V20 = 23.87 vs. 28.73%, P < 0.05). Low dose to heart is increased in left-sided cases (V5 = 14.52 vs. 16.72%, P < 0.05) while same in right-sided cases. The study shows that radiotherapy using the RTOG consensus guidelines improves coverage to target volumes with a nonsignificant increase in normal organ dose compared to that based on anatomical landmarks.

90Y-Labeled Gold Nanoparticle Depot (NPD) Combined with Anti-PD-L1 Antibodies Strongly Inhibits the Growth of 4T1 Tumors in Immunocompetent Mice and Induces an Abscopal Effect on a Distant Non-Irradiated Tumor.

The effectiveness and normal tissue toxicity of a novel nanoparticle depot (NPD) brachytherapy seed incorporating gold nanoparticles (AuNPs) labeled with β-particle emitting, 90Y (termed a "radiation nanomedicine"), were studied for the treatment of 4T1 triple-negative murine mammary carcinoma tumors in Balb/c mice and for inducing an abscopal effect on a distant non-irradiated tumor alone or combined with anti-PD-L1 immune checkpoint antibodies. Balb/c mice with two subcutaneous 4T1 tumors─a primary tumor and a distant secondary tumor were implanted intratumorally (i.t.) in the primary tumor with NPD incorporating 3.5 MBq of 90Y-AuNPs (1 × 1014 AuNPs) or unlabeled AuNPs, alone or combined with systemically administered anti-PD-L1 antibodies (200 μg i.p. three times/week for 2 weeks) or received anti-PD-L1 antibodies alone or no treatment. The primary tumor was strongly growth-inhibited over 14 d by NPD incorporating 90Y-AuNPs but only very modestly inhibited by NPD incorporating unlabeled AuNPs. Anti-PD-L1 antibodies alone were ineffective, and combining anti-PD-L1 antibodies with NPD incorporating 90Y-AuNPs did not further inhibit the growth of the primary tumor. Secondary tumor growth was inhibited by treatment of the primary tumor with NPD incorporating 90Y-AuNPs, and growth inhibition was enhanced by anti-PD-L1 antibodies. Treatment of the primary tumor with NPD incorporating unlabeled AuNPs or anti-PD-L1 antibodies alone had no effect on secondary tumor growth. Biodistribution studies showed high uptake of 90Y in the primary tumor [516-810% implanted dose/g (%ID/g)] but very low uptake in the secondary tumor (0.033-0.16% ID/g) and in normal tissues (<0.5% ID/g) except for kidneys (5-8% ID/g). Very high radiation absorbed doses were estimated for the primary tumor (472 Gy) but very low doses in the secondary tumor (0.13 Gy). There was highdose-heterogeneity in the primary tumor with doses as high as 9964 Gy in close proximity to the NPD, decreasing rapidly with distance from the NPD. Normal organ doses were low (<1 Gy) except for kidneys (4 Gy). No normal tissue toxicity was observed, but white blood cell counts (WBC) decreased in tumor-bearing mice treated with NPD incorporating 90Y-AuNPs. Decreased WBC counts were interpreted as tumor response and not toxicity since these were higher than that in healthy non-tumor-bearing mice, and there was a direct association between WBC counts and 4T1 tumor burden. We conclude that implantation of NPD incorporating 90Y-AuNPs into a primary 4T1 tumor in Balb/c mice strongly inhibited tumor growth and combined with anti-PD-L1 antibodies induced an abscopal effect on a distant secondary tumor. This radiation nanomedicine is promising for the local treatment of triple-negative breast cancer tumors in patients, and these therapeutic effects may extend to non-irradiated lesions, especially when combined with checkpoint immunotherapy.

Potential of Fluid Dynamic Bowtie Filter for Dose Reduction and Image Quality Improvement of Cone-Beam CT

Reducing radiation dose to patients without compromising imaging quality has been an important issue in the medical use of X-ray computed tomography (CT). In this study, based on the conceptual designs of different types of attenuation filters, the radiation doses to patients who undergo a typical head, thorax and abdomen scan using a cone-beam CT with different scanning protocols were simulated using the Monte Carlo method, and the isotropy of the noise power spectrum (NPS) of the reconstructed images was also calculated. Compared to the scanning protocol without attenuation and tube current modulation (TCM), the results showed that the fluid dynamic bowtie filter (FDB) combined with the TCM technique reduced the average organ dose by 70%, 34% and 60% for a typical head, thorax and abdomen scan, respectively, and the NPS isotropy of the reconstructed images was also significantly improved. Compared to most currently used static bowtie filters, the FDB has a higher potential to reduce the dose for patients undergoing CT scans. Further efforts are warranted to make the FDB technique clinically useful.

Target Coverage and Normal Organ Sparing in Dose-Escalated Total Marrow and Lymphatic Irradiation: A Single-Institution Experience.

Purpose/ObjectivesThe aim of this study is to report historical treatment planning experience at our institution for patients receiving total marrow and lymphatic irradiation (TMLI) as part of the conditioning regimen prior to hematopoietic stem cell transplant.Materials/MethodsBased on a review of all historical clinical TMLI treatments plans, we retrieved a 12-Gy cohort of 108 patients with a prescription dose of 12 Gy to the skeletal bones, lymph nodes, spleen, and spinal canal, and retrieved a 20-Gy cohort of 120 patients with an escalated prescription dose of 20 Gy to the skeletal bones, lymph nodes, spleen, and spinal cord, and 12 Gy to the brain and liver. Representative dosimetric parameters including mean and median dose, D80, and D10 (dose covering 80% and 10% of the structure volume, respectively) for targets and normal organs were extracted and compared between the two groups of patients.ResultsFor the 12-Gy cohort, the average mean dose for normal organs ranged from 18.3% to 78.3% of 12 Gy, and the average median dose ranged from 18.3% to 77.5% of 12 Gy. For the 20-Gy cohort, the average mean dose for normal organs ranged from 13.0% to 76.0% of 20 Gy, and the average median dose ranged from 12.5% to 75.0% of 20 Gy. Compared to the mean dose to normal organs in the 12-Gy cohort, the average mean dose to normal organs increased from 0.0% to 73.1%, with only four normal organs showing a >50% increase. Normal organ dose in TMLI plans using volumetric modulated arc therapy fields fell within the dose range in historical TMLI plans.ConclusionDosimetric data in historical TMLI plans at our institution are summarized at prescription dose levels of 12 Gy and 20 Gy, respectively. Compared to the normal organ dose with a prescription dose of 12 Gy, the mean and median dose to most normal organs at an escalated prescription dose of 20 Gy had an increase less than prescription dose scaling. Dosimetric results from this study can be used as reference data to facilitate clinical implementation of TMLI at other institutions.

Validation of RapidPlan Knowledge-Based Model for Volumetric-Modulated Arc Therapy in Prostate Cancer.

This study aims to investigate the viability of using RapidPlan (RP) knowledge-based (KB) treatment plans to initiate the new prostate volumetric-modulated arc therapy (VMAT) plans. The planning data for 120 prostate VMAT treatment plans were entered into the RP system's database. The database of previous VMAT plans was divided into four model groups for training in the RP system. The models were based on the numbers of 20, 60, and 120 prostate VMAT plans. The model of 120 plans used automated priority and manual priority for the optimization process. The models of 20 and 60 plans used only manual priority for optimization. Each model was validated on 15 cases of new prostate cancer patients by comparing RP model plans against manual clinical plans optimized according to the clinical dose constraints. The RP models can estimate the dose comparable target volume to the manual clinical plan, which evaluated values of Dmax, D95%, D98%, HI, and CI and showed comparable results. For the normal organ doses of the bladder, rectum, penile bulb, and femoral head, all RP models exhibited a comparable or better dose than the manual clinical plan, except for the RP models using the automated priority for the optimization process, which cannot control the rectum dose below the dose constraints. The Varian RP KB planning can produce comparable doses or better doses with the clinical manual in a single optimization, although the RP model uses a minimum requirement of the planning number for the model training. The RP models can enhance the efficacy and quality of plans, which depend on the number of VMAT plans used in RP model training for prostate cancer.

Organ doses and normalized organ doses for various age groups in ultralow dose pediatric C-arm cone-beam CT.

To estimate organ dose to major radiosensitive organs during pediatric body C-arm CBCT and determine normalized organ doses using a state-of-the-art equipment. This is a study performed utilizing physical anthropomorphic phantoms. Four anthropomorphic phantoms that simulate the average individual as a neonate, 1-year-old, 5-year-old, and 10-year-old child were used. Personalized Monte Carlo (MC)-based dosimetry was performed to estimate organ doses in children referred to thorax and abdomen C-arm CBCT acquisitions on a recently released latest generation C-arm CBCT system. Age-specific normalized organ doses were generated and organ dose was estimated for skin, bone, breast, lungs, esophagus, thymus, and heart, in the thorax, and liver, adrenals, kidneys, pancreas, stomach, gall bladder, and spleen in the abdomen. Estimated doses were compared to corresponding values obtained with physical measurements performed using thermoluminescent dosimeters (TLD). The results consist of organ doses for thorax and abdomen acquisition protocols. The majority of organs received a dose below 1 mSv. For all ages, the normalized organ doses decreased from neonate to 10-year-old. The difference between the organ doses obtained with MC and TLDs was less than 8%. Normalized organ doses in pediatric C-arm CBCT varied with age. Pediatric C-arm CBCT with latest-generation systems may be performed with sub mGy dose for most organs. • The dose to the majority of organs from pediatric C-arm CBCT is in the sub mSv level. • The normalized organ doses decreased from neonate to 10-year-old. • Reported normalized organ doses may be used to estimate organ dose in pediatric C-arm cone-beam CT on modern equipment.

Evaluation of radiation dose to organs of neonatal patients during portable X-ray examination in incubators: A Monte Carlo simulation study.

Infants admitted to neonate intensive care units (NICUs) are placed in incubators to maintain body temperature and condition, which undergo normal radiographs and are exposed to radiation. Furthermore, different incubator structures in different hospitals exhibit varying object to image receptor distance (OID), source to image receptor distance (SID), presence of canopy, which results in variations in X-ray radiation conditions and doses absorbed by the neonatal patients. To measure organ dose exposed to neonatal patient in different incubator settings. A portable X-ray was performed on a neonatal patient placed in an incubator to identify disease progress, the injection path of the drug, and various factors. To minimize direct contact between neonatal patients and image receptor, radiologic technologists place the image receptor on a tray underneath the incubator and place the portable X-ray tube on top of the acrylic canopy of the incubators. SID and OID settings and value of organ dose exposed to the patient varied based on the incubator structure, and the organ absorbed dose was determined using Monte Carlo N-Particle (MCNP) simulation, PC-based Monte Carlo program (PCXMC) 2.0 simulation, and neonate phantoms. Evaluations of organ dose of neonatal patients in three hospitals with different incubator settings reveal that the average organ dose differs by 36% depending on change in OID and SID settings and reduces by 10% with an acrylic canopy. Therefore, owing to the presence of an acrylic canopy on the top of the incubator and the longer SID with the corresponding shorter OID, a lower dose was absorbed by organs of neonatal patient. Our results provide proof that proper incubator standard decreases organ dose to neonatal patient during continuously diagnostic X-ray procedure.

Total Marrow and Lymphoid Irradiation to 20 Gy Combined With Post-Transplant Cyclophosphamide Graft vs. Host Disease (GvHD) Prophylaxis is Associated With Low Non-Relapse Mortality Rates and Favorable GvHD-Free/Relapse-Free Survival in AML

<h3>Purpose/Objective(s)</h3> Allogeneic hematopoietic cell transplantation (alloHCT) offers the highest curative rate for AML with intermediate or high-risk cytogenetics in remission. GvHD is a main cause of alloHCT mortality and morbidity. This trial evaluated the feasibility of a novel conditioning regimen of total marrow and lymphoid irradiation (TMLI) at 20 Gy combined with post-transplant cyclophosphamide (PTCy), which was designed to reduce the chronic GvHD risks using PTCy and reduce relapse rates with TMLI, thereby improving GRFS rates compared to standard myeloablative conditioning regimens. <h3>Materials/Methods</h3> Eighteen patients with AML in first or second complete remission were treated with TMLI 20 Gy (2 Gy twice daily) to bone, lymph nodes and spleen (liver and brain 12 Gy) on days -4 to 0; stem cell infusion on day 0; PTCy 50 mg/kg/day on days +3 and +4; and tacrolimus 1 mg continuous infusion on days +5 to +90. Endpoints included toxicity, GRFS at 1 year, engraftment, overall survival (OS), and non-relapse mortality (NRM). GRFS was defined as grade 3-4 acute GvHD (aGvHD), chronic GvHD (cGvHD) requiring systemic treatment, relapse, or death (from any cause). <h3>Results</h3> The median age was 40 (range 19-56). Seventeen of 18 patients had intermediate to high-risk cytogenetics. The average (range) Dmean organ doses (Gy) were lungs 8.1 (7.5-9.5), kidneys 7.5 (6.3-9.2), heart 7.3 (6.6-8.3), oral cavity 4.4 (3.0–6.7), esophagus 6.4 (4.7-7.6), upper GI 9.1 (7.3-12.0), lower GI 10.2 (8.9-12.1), and bladder 10.0 (6.8-14.6). Median follow-up was 12.5 months (range 5.9 to 25.4) for surviving patients (n = 17). All patients engrafted. Bearman toxicity data were available for all patients. Grade 2 toxicities were bladder (n = 3) and stomatitis (n = 1). No grade 3-4 toxicities or toxicity-related deaths were observed. aGvHD developed in 2 patients with grade III-IV in only 1 patient (100-day Grade III-IV aGvHD: 5.6%, 95% CI: 0.3-23.1). Five patients developed chronic GvHD with one patient developing moderate to severe cGVHD (1-year cGvHD rate: 28.6%, 95% CI: 7.5%-54.7%). The GRFS rate at 1 year was 60.6% (95% CI: 34.6-79.0). One-year estimates of OS and relapse-free survival were 100% and 83.3% (95% CI: 62.8-96.1), respectively. Disease relapse at 1 year was 16.7% (95% CI: 3.9-37.2). The estimates of NRM at 100 days and 1 year were both 0%. Relapsed disease after transplant occurred in 3 patients (16.7%). One patient died after relapse. <h3>Conclusion</h3> This TMLI 20 Gy only conditioning regimen, together with PTCy and tacrolimus, is associated with low toxicity and NRM. All patients achieved engraftment. Participants with ≥ 1-year follow-up have discontinued immunosuppressive therapy. The results suggest an improved GRFS rate compared to traditional myeloablative regimens reported. A larger phase II trial is planned.

Assessment of Organ and Effective Doses Received by Paediatric Patients Undergoing Computed Tomography Examinations in Three Hospitals in Brazzaville, Congo Republic: An Urgent Necessity for Regulatory Control

The present study aimed at estimating organ and effective doses from computed tomography (CT) scans of paediatric patients in three hospitals in Brazzaville, Congo Republic. A total of 136 data on paediatric patients, from 0.25 (3 months) to 15 years old, who underwent head, chest, abdomen – pelvis (AP) and chest – abdomen – pelvis (CAP) CT scans was considered. The approach followed in the present study to compute organ doses was to use pre-calculated volume CT dose index (CTDIvol) – and 100 milliampere-second (mAs) – normalized organ doses determined by Monte Carlo (MC) simulation. Effective dose were then derived using the international commission on radiological protection (ICRP) publications 60 and 103 formalism. For comparison purposes, effective dose were also computed using dose-length product (DLP) – to – effective dose conversion factors. A relatively high variation in organ and effective doses was observed in each age group due to the dependence of patient dose on the practice of technicians who perform the CT scan within the same facility or from one facility to another, patient size and lack of adequate training of technicians. In the particular case of head scan, the brain and the eye lens were delivered maximum absorbed doses of 991.81 mGy and 1176.51 mGy, respectively (age group 10-15 y). The maximum absorbed dose determined for the red bone marrow was 246.08 mGy (age group 1-5 y). This is of concern as leukaemia and brain tumours are the most common childhood cancers and as the ICRP recommended absorbed dose threshold for induction of cataract is largely exceeded. Effective doses derived from MC calculations and ICRP publications 60 and 103 tissues weighting factors showed a 0.40-17.61 % difference while the difference between effective doses derived by the use of k- factors and those obtained by MC calculations ranges from 0.06 to 224.87 %. The study has shown that urgent steps should be taken in order to significantly reduce doses to paediatric patients to levels observed in countries where dose reduction techniques are successfully applied.

Estimating Specific Patient Organ Dose for Chest CT Examinations with Monte Carlo Method

Purpose: The purpose of this study was to preliminarily estimate patient-specific organ doses in chest CT examinations for Chinese adults, and to investigate the effect of patient size on organ doses. Methods: By considering the body-size and body-build effects on the organ doses and taking the mid-chest water equivalent diameter (WED) as a body-size indicator, the chest scan images of 18 Chinese adults were acquired on a multi-detector CT to generate the regional voxel models. For each patient, the lungs, heart, and breasts (glandular breast tissues for both breasts) were segmented, and other organs were semi-automated segmented based on their HU values. The CT scanner and patient models simulated by MCNPX 2.4.0 software (Los Alamos National LaboratoryLos Alamos, USA) were used to calculate lung, breast, and heart doses. CTDIvol values were used to normalize simulated organ doses, and the exponential estimation model between the normalized organ dose and WED was investigated. Results: Among the 18 patients in this study, the simulated doses of lung, heart, and breast were 18.15 ± 2.69 mGy, 18.68 ± 2.87 mGy, and 16.11 ± 3.08 mGy, respectively. Larger patients received higher organ doses than smaller ones due to the higher tube current used. The ratios of lung, heart, and breast doses to the CTDIvol were 1.48 ± 0.22, 1.54 ± 0.20, and 1.41 ± 0.13, respectively. The normalized organ doses of all the three organs decreased with the increase in WED, and the normalized doses decreased more obviously in the lung and the heart than that in the breasts. Conclusions: The output of CT scanner under ATCM is positively related to the attenuation of patients, larger-size patients receive higher organ doses. The organ dose normalized by CTDIvol was negatively correlated with patient size. The organ doses could be estimated by using the indicated CTDIvol combined with the estimated WED.